The Sinopharm WIBP COVID-19 vaccine, also known as WIBP-CorV, is one of two inactivated virus

COVID-19 vaccine A COVID19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), the virus that causes coronavirus disease 2019 ( COVID19). Prior to the COVID19 pandemic, an e ...

s developed by

Sinopharm China National Pharmaceutical Group Corporation (CNPGC), commonly referred to as Sinopharm, is a Chinese state-owned enterprise. The corporation was the indirect major shareholder of publicly traded companies Sinopharm Group (, via a 51–49 j ...

. Peer-reviewed results show that the vaccine is 72.8% effective against symptomatic cases and 100% against severe cases (26 cases in vaccinated group vs. 95 cases in placebo group). The other inactivated virus COVID-19 vaccine developed by Sinopharm is the BIBP vaccine (BBIBP-CorV) which is comparably more successful. 1 billion doses are expected to be produced per year.

Medical uses

The vaccine is given by

intramuscular injection Intramuscular injection, often abbreviated IM, is the injection of a substance into a muscle. In medicine, it is one of several methods for parenteral administration of medications. Intramuscular injection may be preferred because muscles have ...

. The administered is 2 doses in 3 weeks.

Efficacy

In May 2021, peer-reviewed results published in

JAMA ''The Journal of the American Medical Association'' (''JAMA'') is a peer-reviewed medical journal published 48 times a year by the American Medical Association. It publishes original research, reviews, and editorials covering all aspects of biom ...

of Phase III trials in

United Arab Emirates The United Arab Emirates (UAE; ar, اَلْإِمَارَات الْعَرَبِيَة الْمُتَحِدَة ), or simply the Emirates ( ar, الِْإمَارَات ), is a country in Western Asia (The Middle East). It is located at th ...

and

Bahrain Bahrain ( ; ; ar, البحرين, al-Bahrayn, locally ), officially the Kingdom of Bahrain, ' is an island country in Western Asia. It is situated on the Persian Gulf, and comprises a small archipelago made up of 50 natural islands and an ...

showed that the vaccine is 72.8% effective against symptomatic cases and 100% against severe cases (26 cases in vaccinated group vs. 95 cases in placebo group). 12,743 people received the vaccine and 12,737 people received the placebo in these trials.

Manufacturing

In June 2021, a new factory started production with the capacity to manufacture 1 billion doses annually.

History

In April 2020, China approved clinical trials for a candidate COVID-19 vaccine developed by

's Beijing Institute of Biological Products (BIBP) and the Wuhan Institute of Biological Products (WIBP). Both vaccines are chemically-inactivated whole virus vaccines for

COVID-19 Coronavirus disease 2019 (COVID-19) is a contagious disease caused by a virus, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The first known case was COVID-19 pandemic in Hubei, identified in Wuhan, China, in December ...

. On August 13, 2020, the

Wuhan Institute of Biological Products The Wuhan Institute of Biological Products (WIBP ) or Wuhan Institute of Biology for short is a subsidiary of China National Pharmaceutical Group, a Chinese state-owned enterprise commonly known as Sinopharm. The institute integrates production, ...

published interim results of its Phase I (96 adults) and Phase II (224 adults) clinical studies. The report noted the vaccine had a low rate of adverse reactions and demonstrated

immunogenicity Immunogenicity is the ability of a foreign substance, such as an antigen, to provoke an immune response in the body of a human or other animal. It may be wanted or unwanted: * Wanted immunogenicity typically relates to vaccines, where the injectio ...

, but longer-term assessment of safety and efficacy would require Phase III trials.

Clinical trials

In March 2021,

Cayetano Heredia University Cayetano Heredia University ( es, link=no, Universidad Peruana Cayetano Heredia, UPCH; or simply ''Cayetano Heredia'') is a private nonprofit university located in Lima, Peru. It was named in honor of Cayetano Heredia, one of the eminent Peruv ...

running the BIBP and WIBP trials in Peru announced they were seeking to suspend and unblind participants in the WIBP trials for lower efficacy and offer the participants the BIBP vaccine instead, which was showing efficacy.

Authorizations

On February 25, 2021, China approved the vaccine for general use. According to ''The New York Times'', the vaccine is only approved for limited use in

. On August 19, 2021, the Philippines approved the vaccine for emergency use authorization.

References

External links

{{Authority control Clinical trials Chinese COVID-19 vaccines Inactivated vaccines Products introduced in 2021